Judit Marsillach

List of Publications by Year
in descending order

75 papers	2,693 citations	172457 29 h-index	197818 49 g-index
81 all docs	81 docs citations	81 times ranked	3170 citing authors

#	Article	IF	Citations
1	Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis. Disease Markers, 2022, 2022, 1-9.	1.3	10
2	Paraoxonaseâ€1 (PON1) Status Analysis Using Nonâ€Organophosphate Substrates. Current Protocols, 2021, 1, e25.	2.9	7
3	Paraoxonase-1 and -3 Protein Expression in the Brain of the Tg2576 Mouse Model of Alzheimerâ€™s Disease. Antioxidants, 2021, 10, 339.	5.1	14
4	Paraoxonase-1 and Other HDL Accessory Proteins in Neurological Diseases. Antioxidants, 2021, 10, 454.	5.1	1
5	Interdisciplinary data science to advance environmental health research and improve birth outcomes. Environmental Research, 2021, 197, 111019.	7.5	6
6	Evaluating Gait and Locomotion in Rodents with the CatWalk. Current Protocols, 2021, 1, e220.	2.9	14
7	Paraoxonase 2 deficiency in mice alters motor behavior and causes region-specific transcript changes in the brain. Neurotoxicology and Teratology, 2021, 87, 107010.	2.4	5
8	Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimerâ€™s Disease: A Narrative Review. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	4.0	25
9	HDL Proteome and Alzheimerâ€™s Disease: Evidence of a Link. Antioxidants, 2020, 9, 1224.	5.1	26
10	Paraoxonase (PON1), detoxification of nerve agents, and modulation of their toxicity. , 2020, , 1179-1190.		1
11	Evaluating the link between Paraoxonase-1 levels and Alzheimer's disease development. Minerva Medica, 2019, 110, 238-250.	0.9	26
12	Paraoxonase-1 and Early-Life Environmental Exposures. Annals of Global Health, 2018, 82, 100.	2.0	37
13	Ancient convergent losses of Paraoxonase 1 yield potential risks for modern marine mammals. Science, 2018, 361, 591-594.	12.6	79
14	Metals and Paraoxonases. Advances in Neurobiology, 2017, 18, 85-111.	1.8	17
15	Developmental expression of paraoxonase 2. Chemico-Biological Interactions, 2016, 259, 168-174.	4.0	19
16	Paraoxonases-1, -2 and -3: What are their functions?. Chemico-Biological Interactions, 2016, 259, 51-62.	4.0	145
17	Paraoxonase-3 Is Depleted from the High-Density Lipoproteins of Autoimmune Disease Patients with Subclinical Atherosclerosis. Journal of Proteome Research, 2015, 14, 2046-2054.	3.7	47
18	Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. Journal of Lipid Research, 2014, 55, 1173-1178.	4.2	23

#	Article	IF	Citations
19	Human Valacyclovir Hydrolase/Biphenyl Hydrolase-Like Protein Is a Highly Efficient Homocysteine Thiolactonase. PLoS ONE, 2014, 9, e110054.	2.5	31
20	Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures. Chemico-Biological Interactions, 2013, 203, 85-90.	4.0	12
21	Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clinical Biochemistry, 2013, 46, 1830-1836.	1.9	46
22	Paraoxonase-1 Deficiency Is Associated with Severe Liver Steatosis in Mice Fed a High-fat High-cholesterol Diet: A Metabolomic Approach. Journal of Proteome Research, 2013, 12, 1946-1955.	3.7	54
23	Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology, 2013, 307, 115-122.	4.2	124
24	Protein adducts as biomarkers of exposure to organophosphorus compounds. Toxicology, 2013, 307, 46-54.	4.2	60
25	Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics, 2013, 14, 1495-1515.	1.3	35
26	Paraoxonase-1 Is Associated With Corneal Endothelial Cell Alterations in Patients With Chronic Obstructive Pulmonary Disease. , 2013, 54, 5852.		17
27	Paraoxonase-1 status in patients with hereditary hemochromatosis. Journal of Lipid Research, 2013, 54, 1484-1492.	4.2	20
28	Paraoxonase-1 Inhibits Oxidized Low-Density Lipoprotein-Induced Metabolic Alterations and Apoptosis in Endothelial Cells: A Nondirected Metabolomic Study. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	29
29	Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation. Journal of Lipid Research, 2012, 53, 168-174.	4.2	15
30	Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease. Atherosclerosis, 2012, 220, 545-551.	0.8	24
31	Paraoxonase-1 Is Not Associated with Coronary Artery Calcification in Type 2 Diabetes: Results from the PREDICT Study. Disease Markers, 2012, 33, 101-112.	1.3	10
32	Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study. Disease Markers, 2012, 33, 101-12.	1.3	8
33	Biomarkers of organophosphorus (OP) exposures in humans. NeuroToxicology, 2011, 32, 656-660.	3.0	58
34	Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. Clinical Biochemistry, 2011, 44, 1320-1324.	1.9	16
35	Paraoxonaseâ€1 is only present in traceable amounts in seminal fluid and does not show any relationship with male subfertility. BJU International, 2011, 108, 566-570.	2.5	11
36	Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. European Journal of Clinical Investigation, 2011, 41, 308-314.	3.4	48

#	Article	IF	Citations
37	Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study. Journal of Lipid Research, 2011, 52, 1055-1061.	4.2	21
38	Human PON1, a biomarker of risk of disease and exposure. Chemico-Biological Interactions, 2010, 187, 355-361.	4.0	98
39	Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIVâ€infected patients: relationships with serum markers of oxidation and inflammation. HIV Medicine, 2010, 11, 225-231.	2.2	89
40	Pitfalls in measuring highâ€density lipoprotein cholesterol concentrations in HIVâ€infected patients. HIV Medicine, 2010, 11, 260-265.	2.2	0
41	Paraoxonaseâ€1 Gene Haplotypes Are Associated with Metabolic Disturbances, Atherosclerosis, and Immunologic Outcome in HIVâ€infected Patients. Journal of Infectious Diseases, 2010, 201, 627-634.	4.0	24
42	Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results. Clinical Chemistry and Laboratory Medicine, 2010, 48, 893-4.	2.3	11
43	Hostâ€“pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: The role of CCL2 genetic variants. Cytokine, 2010, 51, 251-258.	3.2	11
44	Paraoxonase-1 in female infertility: a possible role against oxidative stressâ€“induced inflammation. Fertility and Sterility, 2010, 94, 1132-1134.	1.0	12
45	Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids in Health and Disease, 2010, 9, 46.	3.0	32
46	Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. Lipids in Health and Disease, 2010, 9, 32.	3.0	11
47	Interrelationships Between Paraoxonase-1 and Monocyte Chemoattractant Protein-1 in the Regulation of Hepatic Inflammation. Advances in Experimental Medicine and Biology, 2010, 660, 5-18.	1.6	17
48	Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World Journal of Gastroenterology, 2009, 15, 1929.	3.3	45
49	The paraoxonases: role in human diseases and methodological difficulties in measurement. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 83-106.	6.1	215
50	Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1097-9.	2.3	7
51	Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity. Mini-Reviews in Medicinal Chemistry, 2009, 9, 911-920.	2.4	32
52	Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2041-2046.	2.4	60
53	The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clinical Biochemistry, 2009, 42, 91-98.	1.9	59
54	Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology, 2009, 9, 3.	2.0	83

#	Article	IF	Citations
55	Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine, 2009, 48, 273-279.	3.2	48
56	Changes in the expression of genes related to apoptosis and fibrosis pathways in CCl4-treated rats. Molecular and Cellular Biochemistry, 2008, 308, 101-109.	3.1	10
57	Serum Paraoxonase Undergoes Inhibition and Proteolysis During Experimental Acute Pancreatitis. Journal of Gastrointestinal Surgery, 2008, 12, 891-899.	1.7	22
58	Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radical Biology and Medicine, 2008, 45, 146-157.	2.9	162
59	Paraoxonase-1 in Chronic Liver Diseases, Neurological Diseases and HIV Infection. , 2008, , 187-198.		7
60	Paraoxonase 1 and Postprandial Lipemia. , 2008, , 129-138.		0
61	RELATIONSHIP BETWEEN PARAOXONASE-1 (PON1), MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) AND SUB-CLINICAL ATHEROSCLEROSIS IN HIV-1 INFECTED PATIENTS. Atherosclerosis Supplements, 2008, 9, 261.	1.2	0
62	Moderately High Folic Acid Supplementation Exacerbates Experimentally Induced Liver Fibrosis in Rats. Experimental Biology and Medicine, 2008, 233, 38-47.	2.4	14
63	Measurement of serum paraoxonase-1 activity as a potential biomarker for chronic liver impairment. Clinica Chimica Acta, 2007, 386, 114-115.	1.1	18
64	Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis, 2007, 194, 175-181.	0.8	62
65	The results in rodent models of atherosclerosis are not interchangeable. Atherosclerosis, 2007, 195, e85-e92.	0.8	55
66	Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clinical Biochemistry, 2007, 40, 645-650.	1.9	55
67	ADMINISTRATION OF EXOGENOUS ERYTHROPOIETIN Î² AFFECTS LIPID PEROXIDATION AND SERUM PARAOXONASEâ€1 ACTIVITY AND CONCENTRATION IN PREDIALYSIS PATIENTS WITH CHRONIC RENAL DISEASE AND ANAEMIA. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 347-349.	1.9	25
68	Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. Experimental and Molecular Pathology, 2007, 83, 361-366.	2.1	26
69	Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochemical and Biophysical Research Communications, 2006, 340, 1078-1084.	2.1	53
70	Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. Journal of Hepatology, 2006, 45, 51-59.	3.7	82
71	Influence of PON1 Polymorphisms on the Association between Serum Paraoxonase 1 and Homocysteinemia in a General Population. Clinical Chemistry, 2006, 52, 781-782.	3.2	9
72	Longitudinal changes in serum paraoxonase-1 activity throughout normal pregnancy. Clinical Chemistry and Laboratory Medicine, 2006, 44, 880-2.	2.3	15

#	Article	IF	Citations
73	The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clinical Biochemistry, 2005, 38, 1138-1140.	1.9	30
74	Comparison of Paraoxonase 1 Measurements in Serum and in Lithium-Heparin-Anticoagulated Plasma Samples. Clinical Chemistry, 2005, 51, 922-923.	3.2	14
75	Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clinica Chimica Acta, 2005, 361, 206-210.	1.1	35